Virus News and Research

Latest Virus News and Research

Measles still poses threat to domestic and global health security

Fifty years after the approval of an extremely effective vaccine against measles, one of the world's most contagious diseases, the virus still poses a threat to domestic and global health security.

5 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

1950s H2N2 avian influenza A virus still pose threat to human health

St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.

4 Dec 2013

UCI-led study results have important implications for HIV vaccine development

Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself. These results have important implications for HIV vaccine development and for understanding the earliest events in HIV transmission.

4 Dec 2013

Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

St. Jude Children's Research Hospital scientists have identified an enzyme that can halt or possibly even reverse the build-up of toxic protein fragments known as plaques in the brains of mice with Alzheimer's disease. The research appeared in a recent edition of the scientific journal Nature Communications.

3 Dec 2013

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Tel Aviv University researchers discover a protein that kills bacteria

In the arms race between bacteria and modern medicine, bacteria have gained an edge. In recent decades, bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat. Scientists worry that a particularly virulent and deadly "superbug" could one day join the ranks of existing untreatable bacteria, causing a public health catastrophe comparable with the Black Death.

3 Dec 2013

Viewpoints: Where's Obama's 'Mission Accomplished' banner?; health law critics overlooking those denied affordable care in the past

Great news: The White House says that Healthcare.gov and the 36 federally run insurance exchanges are finally good to go. The only thing missing from Sunday's relentlessly upbeat progress report was President Obama in front of a "Mission Accomplished" banner. Sunday's eight-page report was intended to meet Mr. Obama's deadline for fixing the site after its October 1 debut was a calamity. But the more important goal was political -- namely, claiming enough progress to prevent Democrats on Capitol Hill from joining the GOP demand for delaying the individual mandate to buy insurance or even the entire program (12/1).

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Food safety tips for people with HIV/AIDS

December 1, 2013 is World AIDS Day and while the connection between HIV/AIDS (Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) and food safety may not seem obvious, it's actually crucial.

30 Nov 2013

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

Miren Apilánez, researcher in the Department of Paediatrics of the UPV/EHU-University of the Basque Country, has studied the evolution that took place between 1984 and 2011 in paediatric HIV infection in Gipuzkoa. The development of methods to diagnose the disease coupled with increasingly more effective treatments have made it possible to reduce mother-to-child transmission (vertical transmission) from 23.9% to 2.4%, thus virtually eradicating infection in children.

30 Nov 2013

Government of Canada awards $8.76M in funding to develop cure for HIV

In the push for a cure for HIV, the Government of Canada has announced $8.76 million in funding to Université de Montréal and Institut de recherches cliniques de Montréal Professor éric A. Cohen, who will lead an unrivaled group of Canadian investigators and international collaborators with a strong track record of interactive research.

29 Nov 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

Loyola dermatologist offers skin care tips for holidays

The holidays often bring freezing temperatures, limited sleep, sugary treats and cocktails. This combination can spell trouble for your skin, according to a dermatologist at Loyola University Health System.

28 Nov 2013

HIV test for new inmates may not yield new diagnoses, says study

More than 90 percent of HIV-infected inmates entering prison in North Carolina had previously tested positive for the virus, according to a study published in the November 27 issue of the Journal of the American Medical Association.

27 Nov 2013

Virus News and Research

Latest Virus News and Research

Measles still poses threat to domestic and global health security

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

1950s H2N2 avian influenza A virus still pose threat to human health

UCI-led study results have important implications for HIV vaccine development

Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Researchers offer promise of strategy for curing HIV infection

Tel Aviv University researchers discover a protein that kills bacteria

Viewpoints: Where's Obama's 'Mission Accomplished' banner?; health law critics overlooking those denied affordable care in the past

Newly identified protein could prove promising new drug target for AIDS

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Food safety tips for people with HIV/AIDS

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

Government of Canada awards $8.76M in funding to develop cure for HIV

Study brings effective hepatitis C cure closer to reality

Scientists design small synthetic molecules capable of blocking AIDS virus replication

Loyola dermatologist offers skin care tips for holidays

HIV test for new inmates may not yield new diagnoses, says study

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in